Form 4: Actuate Therapeutics Director Receives Stock Option Grant

Director Aaron G.L. Fletcher was granted 15,000 stock options in Actuate Therapeutics, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Aaron G.L. Fletcher acquired 15,000 stock options in Actuate Therapeutics, Inc. (ACTU).
• The options have an exercise price of $2.42 per share.
• The grant date for these options is May 21, 2026.
• The options are set to expire on May 21, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's immediate financial position.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $2.42 exercise price.

Future Outlook

The options vest in full on the first anniversary of the grant date (May 21, 2027).

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to incentivize long-term oversight and strategic alignment.

Comparison to Industry Standards

• The grant of 15,000 options is consistent with typical non-employee director compensation packages for small-cap biotechnology firms.
• Vesting schedules of one year are common for director equity awards in the industry.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of the 15,000 options on May 21, 2027.

Key Dates

Keywords

Actuate Therapeutics, ACTU, Form 4, Insider Trading, Stock Options, Director Compensation